Daniel Gruskin - Aug 6, 2021 Form 4 Insider Report for LogicBio Therapeutics, Inc. (LOGC)

Role
Chief Medical Officer
Signature
/s/ Jonathan Quick, as Attorney-in-Fact
Stock symbol
LOGC
Transactions as of
Aug 6, 2021
Transactions value $
-$6,381
Form type
4
Date filed
8/10/2021, 06:31 PM
Previous filing
May 20, 2021
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LOGC Common Stock Options Exercise +4.8K 4.8K Aug 6, 2021 Direct F1
transaction LOGC Common Stock Sale -$6.38K -1.47K -30.58% $4.35 3.33K Aug 9, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Restricted Stock Units Options Exercise $0 -4.8K -100% $0.00* 0 Aug 6, 2021 Common Stock 4.8K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company").
F2 This sale was made automatically by the Company to cover tax withholding obligations in connection with the vesting and settlement of the RSUs reported in the row above.
F3 These RSUs vested on August 6, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan.